1. Han, B. H., Li, K., Wang, Q. M., et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA oncology. 2018; 4: 1569-1575.
2. Han, B. H., Li, K., Zhao, Y. Z., et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). BrJ Cancer. 2018; 118: 654-661.
3. Cheng, Y., Wang, Q., Li, K., et al. Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC). Ann Oncol. 2019; 30: v711.
4. Chi, Y. H. B. L., Fang, Z. W., Hong, X. N., et al. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clin Cancer Res. 2018; 24: 5233-5238.
5. Zhou, A.-P., Ma, J., Bai, Y., et al. Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial. J Clin Oncol. 2016: 4565-4565.
6. Xie, C. Y., Wan, X. Z., Quan, H. T., et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018; 109: 1207-1219.
7. Sun, Y., Niu, W., Du, F., et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016; 9: 105.
8. Lu, J., Zhong, H., Chu, T., et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur Respir J. 2019; 53: 1801562.
9. Lin, B. Y., Song, X. M., Yang, D. W., Bai, D. S., Yao, Y. Y., and Lu, N. Anlotinib inhibits angiogenesis &ITvia&IT suppressing the activation of VEGFR2, PDGFR beta and FGFR1. Gene. 2018; 654: 77-86.
10. Lu, J., Shi, Q., Zhang, L., et al. Integrated transcriptome analysis reveals KLK5 and L1CAM predict response to anlotinib in NSCLC at 3rd line. Front Oncol. 2019; 9: 886.
11. Lu, J., Zhong, H., Wu, J., et al. Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer. Adv Sci. 2019; 6: 1900721.
12. Liu, Z. J., Wang, J., Meng, Z. T., et al. CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer: Analysis on ALTER-0303 study. Cancer Med. 2018; 7: 3011-3021.
13. Wang, J., Zhao, Y., Wang, Q., et al. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment. Cancer Biol Med. 2018; 15: 443-451.
14. Shen, Y., Lu, J., Hu, F., et al. Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial. J Cancer Res Clin Oncol. 2022; doi: 10.1007/s00432-022-03964-9.
15. Pilotto, S., Bonomi, M., Massari, F., et al. Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'. Curr Pharm Des. 2014; 20: 3958-3972.
16. Li, J., Sun, L., Xu, F., et al. Screening and Identification of APOC1 as a Novel Potential Biomarker for Differentiate of Mycoplasma pneumoniae in Children. Front Microbiol. 2016; 7: 1961.
17. Fujita, K., Kume, H., Matsuzaki, K., et al. Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer. Sci Rep. 2017; 7: 42961.
18. Lee, J., Kim, S. H., Choi, D. S., et al. Proteomic analysis of extracellular vesicles derived from Mycobacterium tuberculosis. Proteomics. 2015; 15: 3331-3337.
19. Lou, Y., Xu, J., Zhang, Y., et al. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. Cell Death Dis. 2021; 12: 170.
20. Lu, J., Xu, W., Qian, J., et al. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells. BMC Med Genomics. 2019; 12: 38.
21. Chu, T., Lu, J., Bi, M., et al. Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer Biol Med. 2021; 18: 816-824.
22. Zhang, Y., Sun, B., Hu, M., et al. CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients. Front Oncol. 2020; 10: 1049.
23. Lu, J., Zhong, R., Lou, Y., et al. TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. Front Immunol. 2021; 12: 732125.
24. Lu, J., Chu, T., Liu, H., et al. Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update. Chin J Cancer Res. 2022; 34, 28-39.
25. Mann, M., and Jensen, O. N. Proteomic analysis of post-translational modifications. Nature Biotechnol. 2003; 21: 255-261.
26. Wulfkuhle, J. D., Liotta, L. A., and Petricoin, E. F. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003; 3: 267-275.
27. Boccellino, M., Pinto, F., Ieluzzi, V., et al. Proteomics analysis of human serum of patients with non‐small‐cell lung cancer reveals proteins as diagnostic biomarker candidates. J Cell Physiol. 2019; 234: 23798-23806.
28. Peng, L., Cantor, D. I., Huang, C., Wang, K., Baker, M. S., and Nice, E. C. Tissue and plasma proteomics for early stage cancer detection. Mol Omics. 2018; 14: 405-423.
29. Jiang, Y., Sun, A., Zhao, Y., et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019; 567: 257-261.
30. Eckert, M. A., Coscia, F., Chryplewicz, A., et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019; 569: 723-728
31. Hristova, V. A., and Chan, D. W. Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev Proteomics. 2019; 16: 93-103.
32. Henderson, M. C., Silver, M., Tran, Q., et al. A noninvasive blood-based combinatorial proteomic biomarker assay to detect breast cancer in women over age 50 with BI-RADS 3, 4, or 5 Assessment. Clin Cancer Res. 2019; 25: 142-149.
33. Lu, J., and Han, B. H. Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy. Technol Cancer Res Treatment. 2018; 17: 1533033818801809.
34. Xu, W., Lu, J., Zhao, Q., et al. Genome-Wide Plasma Cell-Free DNA Methylation Profiling Identifies Potential Biomarkers for Lung Cancer. Dis Markers. 2019; 2019: 4108474.
35. Lu, J., Zhang, Y., Lou, Y., et al. ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients. Front Genet. 2021; 12: 723670.
36. Kim, Y., Jeon, J., Mejia, S., et al. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. Nat Commun. 2016; 7: 1-10.
37. Barnabas, G. D., Bahar-Shany, K., Sapoznik, S., et al. (2019) Microvesicle proteomic profiling of uterine liquid biopsy for ovarian cancer early detection. Mol Cell Proteomics. 2021; 18: 865-875.
38. Loriot, Y., Marabelle, A., Guegan, J. P., et al. Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol. 2021; 32: 1381-1390.
39. Huang, Z., Ma, L., Huang, C., Li, Q., and Nice, E. C. Proteomic profiling of human plasma for cancer biomarker discovery. Proteomics. 2017: 17: 1600240.